07.03.18
Scott Chappel, Ph.D., has been appointed chief scientific officer, iTeos Therapeutics SA. Dr. Chappel reports to chief executive officer Michel Detheux, Ph.D., and will be responsible for expanding the pipeline and leading the preclinical development of the company’s immuno-oncology programs that target the tumor microenvironment to improve the outcomes for cancer patients.
“We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than three decades and is an accomplished scientist who has directed research that has led to the development of several FDA -approved and marketed biological products,” said Dr. Detheux of iTeos. “His experience will be invaluable to the next phase of our growth as we build an attractive pipeline and transition our programs into the clinic.”
Dr. Chappel has significant biotech experience and a strong scientific research and drug development track record. Prior to joining iTeos, he was a founder and chief technology officer at Surface Oncology, where he oversaw all antibody generation, engineering, production and characterization as well as all preclinical IND -enabling studies and GMP manufacturing of antibodies. He was also a founder and chief scientific officer at Arteaus Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer.
“We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than three decades and is an accomplished scientist who has directed research that has led to the development of several FDA -approved and marketed biological products,” said Dr. Detheux of iTeos. “His experience will be invaluable to the next phase of our growth as we build an attractive pipeline and transition our programs into the clinic.”
Dr. Chappel has significant biotech experience and a strong scientific research and drug development track record. Prior to joining iTeos, he was a founder and chief technology officer at Surface Oncology, where he oversaw all antibody generation, engineering, production and characterization as well as all preclinical IND -enabling studies and GMP manufacturing of antibodies. He was also a founder and chief scientific officer at Arteaus Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer.
